<DOC>
	<DOCNO>NCT02578953</DOCNO>
	<brief_summary>This single center , open-label , single dose , randomize 2-way crossover study healthy Japanese male subject fast condition . The study conduct determine bioequivalence dutasteride capsule manufacture GSK ( test product ) dutasteride capsule manufacture Catalent ( reference product ) healthy Japanese male subject . Subjects screen visit within 30 day prior first dose study treatment , two treatment period separate 28-days washout period , re-visit 10-14 day second dose first follow-up second follow via telephone 50-54 day second dose . The total duration study approximately 15 week screen second follow .</brief_summary>
	<brief_title>Bioequivalence Study Dutasteride Capsules Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Titanium dioxide</mesh_term>
	<mesh_term>Butylated Hydroxytoluene</mesh_term>
	<criteria>Between 20 64 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require agree find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 18.524.9 kg/meter square screen . Japanese male . Male subject female partner child bear potential must comply contraception requirement time first dose study medication second followup . Capable give sign informed consent describe include compliance requirement restriction list consent form protocol . ALT bilirubin &gt; 1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Corrected QT interval ( QTc ) &gt; 450 millisecond ( msec ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident . History diabetes peptic ulcer disease uncontrolled medical management . History breast cancer clinical breast examination find suggestive malignancy . History malignancy within past five year , except basal cell carcinoma skin . Subjects prior malignancy evidence disease least past 5 year eligible . Prior medical history evidence prostate cancer ( e.g. , positive biopsy , suspicious ultrasound , suspicious digital rectal examination ( DRE ) ) . Patients suspicious ultrasound DRE negative biopsy within precede 6 month stable prostate specific antigen ( PSA ) eligible study . Creatinine &gt; 1.5xULN . History current condition drug abuse alcoholism . Unable refrain use prescription drug , non prescription drug , vitamin , herbal dietary supplement ( include St John 's Wort ) within 14 day 5 halflives ( whichever longer ) prior first dose study medication . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink . One drink equivalent 350 milliliter ( mL ) beer , 150 mL wine 45 mL 80 proof distil spirit . History regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity study medication , component thereof history drug allergy . The subject positive Serological test syphilis ( Rapid plasma reagin test Treponema pallidum ) , Human immunodeficiency virus ( HIV ) Antigen/Antibody , Hepatitis B surface antigen ( HbsAg ) , Hepatitis C virus ( HCV ) antibody , Human Tcell lymphotropic virus type 1 ( HTLV1 ) antibody screen . A positive prestudy drug screen . Where participation study would result donation blood blood product &gt; =400 mL within 4 month &gt; =200 mL within 1 month . Exposure four new chemical entity within 12 month prior first dose day . The subject participate clinical trial receive investigational product within 4 month prior first dose day current study . The subject currently participate another clinical study postmarketing study subject expose investigational noninvestigational drug device .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Fasted state</keyword>
	<keyword>Japanese male healthy subject</keyword>
	<keyword>Dutasteride</keyword>
</DOC>